As we close out 2016, I’m not surprised to be reporting and commenting on new survey data by the Kaiser Family Foundation showing that 19 million Americans have purchased and imported lower cost medication from Canada and other countries. I suspect the number is higher and I’m sure it’s not high enough, as I’ll discuss at the conclusion of this post.
First, as reported in Kaiser Health News: “As drug prices have spiraled upward in the past decade, tens of millions of generally law-abiding Americans have committed an illegal act in response: They have bought prescriptions outside the U.S. and imported them.” The Kaiser story also reports that many such purchases are made online and while the FDA warns that many online pharmacies are not safe, “…many medicines purchased from another country are the same as the ones patients buy in the U.S.” That’s all true. The key to safety when buying medications internationally is only purchasing from properly verified websites, ones approved by PharmacyChecker.
Just to recap why importation is a lifeline, let’s look at some highlights from recent data. (more…)
Tagged with: AARP, Kaiser Family Foundation, price watch
Yesterday, AARP published its latest Rx Price Watch report, which highlights generic prescription medication price changes from 2006-2013. Generic medication is considered the best avenue towards lower taxpayer and consumer drug costs. In the mid-1980s, passage of the Hatch-Waxman Act helped bring lower cost generic medication to the market faster and fueled intense price competition among generic manufacturers. The result was 1) much lower drug prices on medications that have lost their patents (often 90% lower) and 2) an exceedingly high generic penetration rate with generics comprising 85% of all medication use. AARP’s report suggests that generic drug prices continue to decrease, which is good, but at a much slower rate, “indicating that the era of consistent generic drug price decreases may be coming to an end.”
Stay calm. Generics are still usually much lower cost than the brand names and that will continue to be the case. AARP’s report notes that 2013 had the lowest average generic price decrease (4.1%) since 2006. However, AARP’s data also shows considerable fluctuation in this rate, enough to question whether or not we’re really experiencing a new normal in which generic drug prices no longer decline year after year. For example, the decreases in average generic drug prices that occurred in the prior two years, 2011 and 2012, 9.1% and 14.5%, respectively, were the highest since 2006. These numbers, however, most likely reflect what’s referred to as the “patent cliff” – a time when many patents on blockbuster brand name drugs, such as Lipitor and Plavix, lost their patents, thus allowing much lower cost generics to enter the market. As I see it, we don’t really know the future trend of generic drug prices.
Again, most generic drugs are way cheaper than their brand name counterparts and just as safe and effective. The big generic drug problem is that the cost of some generics has spiked outrageously over the past few years, sometimes beyond the reach of the American consumer. Usually when we talk about insane price increases of brand name drugs year over year the percentages are 10, 20, 30 or even 40%. But the increases for some generics have literally been in the 2000% range! One crazy example, reported by the People’s Pharmacy, showed that the cost of the antibiotic doxycycline skyrocketed from six cents ($.06) to $3.30, a 5500% increase.
In fact, directing you back to our research from November 2014, we found that even brand name versions sold in foreign pharmacies can be MUCH lower cost than the generics sold here! Please keep in mind that those same generics mentioned in our analysis may have already come down in price domestically. So before you buy from an international online pharmacy, check your local pharmacy first.
Tagged with: AARP, brand name drugs, Doxycycline, generic drugs, Hatch-Waxman Act, Lipitor, Plaxvix, The People's Pharmacy
Today, the AARP reported that brand name drug prices increased by 41% between 2006-2009, approximately three times the rate of inflation. In the New York Times article announcing the study, AARP refers to the price increases as “relentless”. The media often reports on studies about drug price increases because it’s an issue of great frustration for millions of Americans; and this blog has presented the facts on how tens of millions of Americans skip medication due to cost. But what are the public health ramifications of high drug costs? (more…)
Tagged with: AARP, drug prices out of reach, durg price study